Utilisation of the ESMO-MCBS in practice of HTA

Annals of Oncology

Volumn 27, Issue 11, 2016, Pages 2134-2136

  Wild, C ^a   Grossmann N ^a   Bonanno, P V ^b   Bucsics, A ^c   Furst, J ^d   Garuoliene, K ^e   Godman, B ^f,g   Gulbinovic, J ^h   Jones, J ⁱ   Pomorski, M K ^j   Emprechtinger, R ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b Independent Pharmaceutical Consultant   (Malta)

^c UNIVERSITY OF VIENNA   (Austria)

^d Health Insurance Institute of Slovenia   (Slovenia)

^e National Health Insurance Fund   (Lithuania)

^f UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h VILNIUS UNIVERSITY   (Lithuania)

ⁱ HEALTHCARE IMPROVEMENT SCOTLAND   (United Kingdom)

^j Agency for Health Technology Assessment in Poland   (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; AFLIBERCEPT; ANTINEOPLASTIC AGENT; CRIZOTINIB; ERLOTINIB; GEFITINIB; IPILIMUMAB; NIVOLUMAB; PACLITAXEL; REGORAFENIB; TRAMETINIB; VEMURAFENIB;

AUSTRIA; BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER SURVIVAL; CLINICAL PRACTICE; COLORECTAL CARCINOMA; CORRELATIONAL STUDY; DRUG INDICATION; DRUG SAFETY; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HUMAN; LETTER; LUNG CANCER; MEDICAL SOCIETY; MELANOMA; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; NON SMALL CELL LUNG CANCER; ONCOLOGY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SCORING SYSTEM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY;

HUMANS; MEDICAL ONCOLOGY; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 85021092906     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw297     Document Type: Letter

References (8)

1. Cherny N, Sullivan R, Dafni U et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26(8): 1547-1573
2. Nachtnebel A, Breuer J, Willenbacher W et al. Looking back on 5 years of Horizon Scanning in Oncology. Int J Technol Assess Health Care 2016; 1(3): 1-7
3. Hartmann M. The ESMO magnitude of clinical benefit scaling tool: from theory to practice. Ann Oncol 2015; 26(11): 2357-2358
4. Garattini S, Bertele V, Godman B et al. Enhancing the rational use of new medicines across European health care systems. Eur J Clin Pharmacol 2008; 64(12): 1137-1138
5. Godman B, Malmström R, Diogene E et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol 2015; 8(1): 77-94
6. Grössmann N, Wild C, Mayer J. Onkologika: übersicht zu Nutzenbewertungen und Refundierungspolitiken in Europa. LBI-HTA Rapid Report Nr. 8. Vienna: 2016
7. Muhonen T, Joensuu H, Pfeiffer P. Comment on ESMO magnitude of clinical benefit scale. Ann Oncol 2015; 26(12): 2504
8. Cherny N, Sullivan R, Dafni U et al. Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al. Ann Oncol 2016; 27(1): 203-205